Glenmark Pharmaceuticals Inc., USA has unveiled the lacosamide oral solution at a concentration of 10 mg/mL. This product matches the bioequivalence and therapeutic effects of the reference drug, Vimpat Oral Solution at the same strength, originally produced by UCB, Inc.
Based on IQVIA sales reports, the Vimpat oral solution market, at 10 mg/mL, reached annual revenues of roughly $57.0 million for the year concluding in October 2024.
Marc Kikuchi, who leads as president and business head for North America, expressed enthusiasm for the introduction, emphasizing Glenmark’s ongoing dedication to offering patients high-quality and cost-effective therapeutic options.
Glenmark’s existing US portfolio consists of 201 products ready for distribution, with an additional 51 ANDA applications currently awaiting FDA approval. Apart from its internal product submissions, Glenmark is actively pursuing partnerships for external development to boost the expansion and diversification of its existing product line.
Glenmark Pharmaceuticals Ltd. stands as a research-focused, worldwide pharmaceutical corporation with operations spanning branded, generic, and over-the-counter medications. Their commitment lies in the fields of respiratory health, dermatology, and cancer care, supported by 11 state-of-the-art manufacturing sites across four continents and activities in over 80 nations.